Site-specific uncoupling and inhibition of oxidative phosphorylation by biguanides
If any of these sound like your week, you are in exactly the right place: Youre scared of losing your muscle, your hair, or ending up with that gaunt, drained Ozempic face. You open the fridge and nothing sounds good, so you barely eat
To date, all randomized studies evaluating the trajectory of body weight upon discontinuation of drugs used to treat obesity, starting from the STORM study that used sibutramine for 2 years [149], have consistently shown significant weight regain upon therapy cessation [150]
However, using it for unapproved conditions without a prescription is illegal

Glossary GLP-1 Glucagon-like peptide-1 GLP-1R GLP-1 receptor GLP-1Ras GLP-1R agonists DPP4 Dipeptidyl peptidase 4 GRPP Glicentin-related pancreatic polypeptide cAMP Cyclic adenosine monophosphate T2DM Type 2 Diabetes Mellitus PKA Protein Kinase A RGNEF4 Rap Guanine Nucleotide Exchange Factor 4 IP3 Inositol triphosphate pathway DAG Diacylglycerol CNS Central Nervous System BBB Blood Brain Barrier AD Alzheimers Disease PD Parkinsons Disease ROS Reactive Oxygen Species BDNF Brain-Derived Neurotrophic factor LTP Long Term Potentiation Ex-4 Exendin-4 MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine CVOTs CV outcome trials CRP C-reactive protein SCALE Satiety and Clinical Adipose Liraglutide Evidence STEP Semaglutide Treatment Effect in People with Obesity BMI Body Mass Index VLDL Very low-density lipoprotein LDL Low-density lipoprotein ApoB48 Apolipoprotein B48 EAT Epicardial adipose tissue DPP-4i Dipeptidyl peptidase-4 inhibitors SGLT-2i Sodium-glucose cotransporter-2 inhibitor RGCs Retinal Ganglion Cells IOP Intraocular pressure DR Diabetic Retinopathy GDM Gestational Diabetes Mellitus PAI-1 Plasminogen activator inhibitor type 1 VAM Vascular adhesion molecule PCOS Polycystic ovarian syndrome FH Functional hypogonadism References 1 GraafCdDonnellyDWoottenDLauJSextonPMillerMet al
.webp)